1990
DOI: 10.1016/s0954-6111(08)80040-6
|View full text |Cite
|
Sign up to set email alerts
|

Risk factors for hydrocortisone myopathy in acute severe asthma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
23
0
5

Year Published

1993
1993
2013
2013

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 78 publications
(29 citation statements)
references
References 11 publications
1
23
0
5
Order By: Relevance
“…Consequently, acute atrophy and rhabdomyolysis might have been induced in these studies. This has also been observed in patients treated acutely with massive doses ofcorticosteroids (26)(27)(28)(29)(30). Their pattern of acute generalized muscle atrophy and weakness, however, is distinctly different from the (6) 35 (6) Mean±SD.…”
Section: Discussionmentioning
confidence: 63%
“…Consequently, acute atrophy and rhabdomyolysis might have been induced in these studies. This has also been observed in patients treated acutely with massive doses ofcorticosteroids (26)(27)(28)(29)(30). Their pattern of acute generalized muscle atrophy and weakness, however, is distinctly different from the (6) 35 (6) Mean±SD.…”
Section: Discussionmentioning
confidence: 63%
“…Consequently, acute atrophy and rhabdomyolysis might have been induced in these studies. This has also been observed in patients with acute air ways obstruction, treated with massive doses of corticosteroids (8,(24)(25)(26). This pattern of acute generalized muscle atrophy and weakness, however, is distinctly different from the clinical pat tern observed during chronic steroid myopathy.…”
Section: Discussionmentioning
confidence: 76%
“…32 No known therapy exists to prevent or enhance recovery after the development of steroid-induced myopathy although physical activity has been reported to prevent its development. 33,34 Our analysis suggests that steroid myopathy is a relatively common complication of high-dose steroid therapy for aGVHD. We limited our analysis to patients with AML/MDS and to patients surviving at least 100 days post transplant to avoid the confounding factors of prior steroid therapy as treatment for the primary malignant disorder, and early deaths from other transplant complications immediately after institution of steroid therapy for aGVHD.…”
Section: Discussionmentioning
confidence: 92%